Erick Gamelin - Mar 1, 2024 Form 4 Insider Report for Acrivon Therapeutics, Inc. (ACRV)

Role
Chief Development Officer
Signature
/s/ Rasmus Holm-Jorgensen, Attorney-in-Fact
Stock symbol
ACRV
Transactions as of
Mar 1, 2024
Transactions value $
$0
Form type
4
Date filed
11/27/2024, 06:08 PM
Previous filing
Feb 16, 2024
Next filing
May 16, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ACRV Stock Option (Right to Buy) Award $0 +45K $0.00 45K Mar 1, 2024 Common Stock 45K $5.70 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Twenty-five percent (25%) of the shares subject to the option vest on March 1, 2025, and the remaining shares subject to the option vest in 36 substantially equal monthly installments thereafter, in each case subject to the Reporting Person's continuous service through each vesting date.